Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Rochester
This is a prospective observational study of patients receiving reslizumab to treat their asthma. Some asthma patients receiving reslizumab also have CRS, which might also be improved by this drug. Study measures will be obtained from the medical records of eligible subjects who consent to participate. The study has no specific procedures per se, because all study measures are acquired during the course of standard of care treatment and will be abstracted from those medical records.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age is 18 years or older
Physician diagnosis of poorly controlled moderate to severe asthma despite typical medical therapy with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment)
Initiating or undergoing reslizumab therapy (Reslizumab - Patient Information listed in Appendix 1 for reference)
Physician diagnosis of chronic rhinosinusitis with nasal polyposis
Able to understand and willing to provide informed consent
Able to complete standard of care English-language questionnaires
You may not be if
Current smokers
Significant uncontrolled medical conditions
Ongoing malignancy or history of cancer in remission for less than 12 months
Subjects who had received immunosuppressive medications within 3 months of enrollment